Lexaria Bioscience Corp. revenue by segment LEXX

Annual Quarterly

Lexaria Bioscience Corp. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Aug 31, 2025 was IP Licensing at $696,000, 99% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 May 31, 2026	FY 2025 Aug 31, 2025	FY 2024 Aug 31, 2024	FY 2023 Aug 31, 2023	FY 2022 Aug 31, 2022	FY 2021 Aug 31, 2021	FY 2020 Aug 31, 2020	FY 2019 Aug 31, 2019	FY 2018 Aug 31, 2018	FY 2015 Aug 31, 2015	FY 2011 Oct 31, 2011
Revenue	0	1	0	0	0	1	0	0	0	—	—
IP Licensing	0 -68.0% share 100.0%	1 +52.0% share 98.6%	0 share 98.6%	—	—	—	—	—	—	—	—
B2 B	—	—	—	—	—	0 +96.1% share 41.1%	0 share 39.4%	—	—	—	—
B Two B	0 -100.0% share 0.0%	0 +84.2% share 1.4%	0 share 1.2%	—	—	—	—	—	—	—	—
Other Revenue	—	—	0 share 0.2%	—	—	—	—	—	—	—	—
R And D	—	—	0 -97.4% share 0.2%	0 -35.7% share 15.6%	0 share 21.5%	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LEXX (Nasdaq)
Fiscal year ends: August 31
Incorporated in: NV
Headquarters: Kelowna, British Columbia, Canada
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1348362
Former names: Lexaria Corp. (until May 11, 2016); LEXARIA CORP. (until May 11, 2016)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.